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a b s t r a c t
This study was conducted to compare the characteristics of patients, with and without
diabetes mellitus, presenting with myocardial infarction (MI) and treated with coronary
artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or thrombolytic
therapy. Factors related to mortality due to MI in Iran were also determined. This study was
a prospective analysis. To analyze the data, Stata software (chi square, t test, Cox and logistic
regression) was used. Participants were patients hospitalized for MI for the first time in 540
hospitals from April, 2012 to March, 2013. Out of 20,750 patients with MI, 461 2 (22.3%) had
type 2 diabetes. MI case fatality rate was 13.22% (95%CI: 12.24–14.19) and 11.78% (95%CI:
11.28–12.27) in patients with and without diabetes, respectively. The rates of CABG, PCI, and
thrombolytic therapy use were 4.2%, 8%, and 58% in patients with diabetes, and 2.1%, 6.5%,
and 55% in patients without diabetes. The odds ratio of mortality for ST segment elevation
myocardial infarction (STEMI) and chest pain resistant to treatment was, respectively, 6.3
and 2.8 in those with diabetes, and 3.9 and 3.7 in patients without diabetes. The hazard ratio
of mortality for gender, education, smoking, left bundle branch block, PCI, and type of MI
was different between the two groups (P < 0.05). Characteristics of patients dying post MI
were different in those with or without diabetes mellitus. Although use of CABG, PCI, and
thrombolytic therapy was more frequent in patients with diabetes than without, mortality
was higher in diabetes patients.
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Despite decreases in morbidity and mortality rates due to
cardiovascular diseases in most developed countries, these
diseases have become the most important health challenge
and cause of mortality in many developing countries
worldwide, including the Islamic Republic of Iran. Myocardial
Infarction (MI) is the leading reason for mortality in this
country [1–3]. Type 2 diabetes has an important role in
mortality from MI [3–5]. A study in Japan showed that, among
patients with MI, diabetes was not an independent predictor of
hospital mortality [6]. Type 2 diabetes is one of the most
common metabolic disorders in the world. Most people with
type 2 diabetes live in low- and middle-income countries and
these will experience the greatest increase in cases of diabetes
over the next 22 years. [7]. In Iran, type 2 diabetes prevalence
varies between 4.2% and 15.9% in general population [8–10].
Diabetes is the 9th and 16th leading reason for death in women
and men, respectively in Iran [11,12]. Use of treatments such as
coronary artery bypass grafting (CABG), percutaneous coro-
nary intervention (PCI), and thrombolytic therapy has lowered
mortality from ischemic heart disease, but these procedures
do not lead to similar outputs for all patients [13–15]. In Iran,
no study has been yet conducted to compare the character-
istics of new MI cases in those with and without diabetes
undergoing pharmaco-invasive therapy nor to establish the
factors related to mortality from MI. Therefore, the contribu-
tion of type 2 diabetes to the risk and outcome of MI remain
unspecified in this country and relevant healthcare decisions
in Iran’s health system are made based on research conducted
in other countries [16]. This study was conducted to determine
and compare the characteristics of patients with or without
diabetes who underwent pharmaco-invasive therapy post MI,
and to determine the factors contributing to mortality.
2. Materials and methods
This study was a prospective analysis of data obtained from
the Myocardial Infarction Registry of Iran’s Cardiovascular
Diseases Surveillance System. 20,750 patients hospitalized
with a new presentation with MI (across 540 hospitals)
between April 2012 to March 2013 were included. The study
protocol was approved by the Management Center of Non-
Communicable Diseases and Office of Cardiovascular Diseases
Prevention of Iran Ministry of Health and Medical Education
(approval no. 305/837). Inclusion criteria were based on the
World Health Organization (WHO) and World Heart Federation
definition of myocardial infarction diagnosis as per the
International Classification of Diseases (ICD10) codes I21, I22
[17]. Patients with prior myocardial infarction history or no
definite diagnosis by a cardiologist were excluded from the
study. Data on age, gender, education, ischemic heart disease
symptoms, duration of hospital stay, smoking, dyslipidemia,
hypertension, heart failure, and family history of cardiovas-
cular diseases were collected. Confirmation of presence of
type 2 diabetes was by fasting blood glucose test and levels of
glycosylated hemoglobin (HbA1C) obtained from the patients’
medical records. Diabetes was confirmed when fasting plasmaglucose (FPG) 7 mmol/L or when a participant self reported
having been diagnosed by a physician and was on medication
for type 2 diabetes [9,10,18]. After definite diagnosis of MI by a
cardiologist, data on left bundle branch block (LBBB), right
bundle branch block (RBBB), atrial fibrillation, ventricular
and atrial tachycardia, type and location of MI, and use of
therapeutic regimens like CABG, PCI, and thrombolytic
therapy were gathered. Hospital mortality from MI was
determined as a dependent variable. To analyze the data,
chi-square, t test, and two regression models were conducted.
Odds ratio (OR) and hazard ratio (HR) of death for clinical and
demographic risk factors were calculated by logistic regres-
sion and Cox regression, respectively. The cohort of patients
was defined by the date at MI diagnosis, hospital stay, and
follow-up till discharge or death (disease outcome). HR of
death was calculated and reported as crude and adjusted rates
for those with and without diabetes by seven Cox proportional
hazards models. First, univariate analysis was used. To control
for confounders, we entered the variables which were
significant or approximately significant into a multiple
regression model. Stata software (Stata Corp. 2011. Stata
Statistical Software: Release 12. College Station, TX: Stata Corp
LP) was used and P < 0.05 was considered significant.
3. Results
Of 20,750 new MI patients, 4612 had type 2 diabetes. The
prevalence of diabetes was thus 22.3% and 58.5% were men.
Mean  standard deviation of age at the time of MI was
61.9  11.7 and 60.9  13.8 years for those with or without
diabetes mellitus, respectively. The mean duration of hospi-
talization was 6.5 days for all patients and similar for those
with or without diabetes (P > 0.05). Data on age groups,
education, gender, and medical history are shown in Table 1.
Out of 2834 type 2 diabetes patients presenting with STEMI,
224 (7.9%) died within a year. MI case fatality rate (CFR) was
13.22% (95%CI: 12.29–14.19) and 11.78% (95%CI: 11.28–12.27),
respectively, in those with or without diabetes (P = 0.008).
58.4% of patients with type 2 diabetes were between 30 and 64
years old. The prevalence of hypertension was 52.8% and
30.6% in those with or without diabetes, respectively. The
prevalence of heart failure was 28.2% in those with type 2
diabetes patients. The prevalence of respiratory distress and
vomiting was 6% and 3.3% in those with diabetes and 5.2% and
2.6% in those without diabetes, (P < 0.05). No significant
difference was seen for other complaints and symptoms prior
to MI including sweating, nausea, and jaw pain in those with
or without diabetes (P > 0.05). The proportion of CABG, PCI,
and thrombolytic therapy use was, respectively, 4.2%, 8%, and
58% in those with diabetes and 2.1%, 6.5%, and 55% in those
without diabetes. Mortality following PCI and CABG was 7.28%
and 15.74% in those with diabetes and 4.72% and 11.4% in
those without diabetes. Mortality following the above thera-
pies was significantly higher in those with diabetes without
(P < 0.001). Mortality following thrombolytic therapy in
patients with diabetes was significantly less than in those
without (13.23% vs. 15.57%, P < 0.05). Comparison of clinical
characteristics between the two groups of patients is shown in
Table 2. Determinants of mortality were different in multiple
Table 1 – Demographic details for patients presenting with new MI.
Characteristic Total (%) With type 2 diabetes Without type 2 diabetes P value
Sample size 20,750 4612 (22.2%) 16,138 (77.8%) –
Age (mean  SD) (years) 61.2  13.4 61.9  11.7 60.9  13.8 <0.05*
Hospital stay (days) 6.5  14.6 6.6  14.7 6.5  14.5 0.814
Gender
Men 15,033 (72.4) 2701 (58.5) 12,332 (76.4) <0.05*
Women 5717 (27.6) 1911 (41.5) 3806 (23.6)
Education
Illiteracy 9611 (46.3) 2243 (48.6) 736 8(45.6) <0.05*
Primary 4941 (23.8) 1144 (24.8) 3797 (23.5)
Guidance 1940 (9.3) 370 (8.1) 1570 (9.7)
High school 2992 (14.4) 613 (13.3) 2379 (14.7)
University 1266 (6.1) 242 (5.2) 1024 (6.3)
Smoker 5443 (26.2) 1107 (24) 4336 (26.8) <0.05*
Family history of MI 4293 (20.6) 1290 (27.9) 3003 (18.6) <0.05*
Hypertension 7376 (35.5) 2435 (52.8) 4941 (30.6) <0.05*
High cholesterol 3710 (17.8) 1572 (34) 2138 (13.2) <0.05*
Heart failure 1682 (8.1) 474 (28.2) 1208 (71.8) <0.05*
* P value less than 0.05 to be assumed significant.
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education, smoking, hypertension, and PCI use was significant
in patients without diabetes and non significant for those with
diabetes. The OR (95% CI) for the above variables is shown in
Table 3. Chest pain resistant to treatment amongst patients
with diabetes mellitus gave the highest OR of mortality (6.3)
followed by ventricular tachycardia (3.4), lack of thrombolytic
therapy (3.1), and heart failure (2.2). Correspondingly, the
highest OR of mortality amongst patients without diabetes
patients was chest pain resistant to treatment (3.7) followed by
lack of thrombolytic therapy (2.9), and MI in the family history
(2.1). The HR for mortality was different between those with or
without diabetes. Amongst diabetes patients, the highest HR
of death was for STEMI (3.01) followed by chest pain resistant
to treatment (2.9), ventricular tachycardia (2.6), lack of
thrombolytic therapy (2.5), family history of MI (1.6), and LBBB
(1.5) (Table 4). HR of death by gender, education, smoking, highTable 2 – Clinical characteristics of MI presentation.
Characteristic Total (%) With type 2 d
AF 511 (2.5) 143 (3.1
VT 1198 (5.8) 205 (4.5
RBBB 289 (1.4) 82 (1.7
LBBB 383 (1.8) 97 (2.1
Lateral MI 990 (4.8) 186 (4) 
Anterior MI 4332 (20.9) 892 (19.
Inferior MI 7179 (34.6) 1578 (34.
Posterior MI 853 (4.2) 175 (3.8
STEMI 15,729 (75.8) 2834 (61.
Death 2511 (12.1) 610 (13.
PCI 1431 (6.9) 371 (8) 
CABG 539 (2.6) 197 (4.2
Lack of thrombolytic 9222 (44.5) 1939 (42)
Therapy
Chest pain 2229 (10.7) 505 (10.
AF—atrial fibrillation; VT—ventricular tachycardia; RBBB—right bundl
infarction; STEMI—ST-segment elevation myocardial infarction; NSTEM
neous coronary intervention; CABG—coronary artery bypass grafting.
* P < 0.05 to be assumed significant.cholesterol, LBBB, and PCI treatment was different in those
with or without diabetes. The HR of death after adjusting for
variables is shown in Table 5.
4. Discussion
In the present study, the characteristics of new MI patients
with and without type 2 diabetes, undergoing conventional
therapies were determined and compared. After controlling
for confounders, we found that, the HR of mortality for MI was
significantly higher in type 2 diabetes patients than in patients
without diabetes. Additionally, the determinants of mortality
from MI were different in those with or without diabetes. Use
of PCI and CABG among diabetes patients appears consider-
ably lower in Iran than in some other countries [19,20]. The
study of Gnavi et al. showed that, mortality from MI in thoseiabetes Without type 2 diabetes P value
) 545 (3.3) >0.05
) 993 (6.2) <0.05*
) 207 (1.2) <0.05*
) 286 (1.7) >0.05
804 (5) <0.05*
3) 3440 (21.3) <0.05*
2) 5601 (34.7) >0.05
) 678 (4.2) >0.05
4) 10,271 (63.6) <0.05*
2) 1901 (11.7) <0.05*
1060 (6.5) <0.05*
) 342 (2.1) <0.05*
 7283 (45) <0.05*
9) 1724 (10.6) >0.05
e branch block; LBBB—left bundle branch block; MI—myocardial
I—non ST-segment elevation myocardial infarction; PCI— percuta-
Table 3 – Adjusted odds ratio and mortality.
Characteristics With type 2 diabetes Without type 2 diabetes
OR CI P-value OR CI P-value
Standardized age (year) 1.32 1.1–1.4 0.001 1.5 1.4–1.6 0.001
Women 1.09 0.8–1.3 0.424 1.2 1.1–1.4 0.001
Education
Illiterate 1.1 0.6–1.8 0.61 0.93 0.1 0.555
Primary 0.96 0.5–1.5 0.877 0.81 0.08 0.068
Guidance 1.1 0.6–2 0.001 0.64 0.08 0.001
High-school 1 0.6–1.7 0.855 0.69 0.08 0.002
University Ref. – – – – –
Smoking 1.05 0.8–1.3 0.637 1.2 1.08–1.3 0.001
Family history 2.07 1.67–2.56 0.001 2.1 1.9–2.4 0.001
Hypertension 0.85 0.6–1.06 0.159 0.8 0.7–0.91 0.001
High cholesterol 0.80 0.64–0.99 0.046 0.91 0.7–1.07 0.285
Chest pain 6.3 4.9–8 0.001 3.7 3.3–4.3 0.001
Lack of thrombolytic therapy 3.1 2.5–3.9 0.001 2.9 2.6–3.3 0.001
RBBB 2.07 1.1–3.7 0.017 1.7 1.1–2.5 0.004
VT 3.4 2.4–4.9 0.001 1.8 1.5–2.2 0.001
STEMI 2.8 2.3–3.6 0.001 3.9 3.5–4.4 0.001
PCI 0.81 0.5–1.2 0.364 0.62 0.4–0.85 0.003
CABG 0.96 06–1.5 0.881 0.88 0.6–1.2 0.495
Heart failure 2.26 1.7–2.9 0.001 1.4 1.1–1.67 0.001
Lateral MI 2.05 1.3–3.1 0.001 2.03 1.64–2.5 0.001
OR—odds ratio; SE—standard error; RBBB—right bundle branch block; VT—ventricular tachycardia; STEMI—ST-segment elevation myocardial
infarction; PCI—percutaneous coronary intervention; CABG—coronary artery bypass grafting; MI—myocardial infarction.
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suggesting lower mortality rate than in Iran. Higher mortality
from MI in Iran than in other countries could be explained by
less frequent use of PCI, CABG, and thrombolytic therapy.Table 4 – Hazard ratio of various factors* and mortality.
Characteristics With type 2 diabetes 
HR CI 
Age (year) 1.21 1.09–1.34 
men 0.84 0.7–1.01 
Education
Illiterate 0.95 0.63–1.4 
Primary 0.84 0.55–1.2 
Guidance 0.94 0.58–1.5 
High-school 0.84 0.54–1.3 
university Ref. – 
Smoking 0.97 0.8–1.17 
Family history 1.62 1.36–1.93 
Hypertension 0.84 0.7–1.01 
High Cholesterol 0.78 0.65–0.94 
Chest pain 2.91 2.3–3.5 
Lack of thrombolytic therapy 2.58 2.1–3 
RBBB 1.52 0.97–2.3 
VT 2.6 1.9–3.4 
STEMI 3.01 2.7–3.3 
PCI 0.79 0.53–1.1 
CABG 1.1 0.75–1.6 
Heart failure 1.4 1.1–1.8 
LBBB 1.55 1–2.3 
VT—ventricular tachycardia; STEMI—ST-segment elevation myocardia
therapy; PCI—percutaneous coronary intervention.
* The variables were entered as dichotomous (0 & 1) and 0 was set as reJuutilainen et al. conducted a study on diabetes patients and
found that, HR of mortality was 0.9 (95% CI: 0.6–1.5) and was
not significant in diabetes patients with MI history compared
to non-diabetes patients without the history of MI [22]. In ourWithout type 2 diabetes
P-value HR CI P-value
0.001 1.3 1.2–1.38 0.001
0.073 0.76 0.68–0.85 0.001
0.61 0.86 0.7–1.06 0.555
0.877 0.81 0.6–1 0.068
0.001 0.68 0.52–0.89 0.001
0.855 0.74 0.58–0.94 0.002
– – – –
0.797 1.16 1.05–1.28 0.003
0.001 1.71 1.5–1.8 0.001
0.065 0.84 0.75–0.93 0.001
0.01 0.92 0.8–1.06 0.270
0.001 2.5 2.2–2.7 0.001
0.001 2.2 2–2.4 0.001
0.06 2.2 1.6–3 0.001
0.001 1.5 1.35–1.8 0.001
0.001 2.3 1.92–2.8 0.001
0.264 0.70 0.52–0.93 0.015
0.607 0.78 0.56–1.08 0.138
0.001 1.2 1.03–1.4 0.017
0.048 0.79 0.6–1 0.114
l infarction; RBBB—right bundle branch block; TT—thrombolytic
ference.
Table 5 – Modeling of hazard ratio (95% confidence interval) for mortality in patients with type 2 diabetes in comparison to
patients without type 2 diabetes.
Models Type 2 diabetes
0 Unadjusted HR 1.1:1–1.2
P < 0.039
1 Adjusted for age and gender 1.06:0.97–1.1
P = 0.176
2 Above + adjusted for education and interaction of gender with education 1.06:0.97–1.16
P = 0.173
3 Above + past medical history 1.07:0.97–1.18
P = 0.151
4 Above + treatment regime 1.13:1.03–1.24
P = 0.01
5 Above + ischemic pattern pain 1.15:1.04–1.26
P = 0.004
6 Above + complication of MI 1.12:1.01–1.23
P = 0.022
7 Above + MI type 1.13:1.02–1.24
P = 0.013
Model 2: age + gender + interaction of gender with education. Model 3: smoking + type 2 diabetes mellitus + hypertension + hyperlipidaemia.
Model 4: percutaneous coronary intervention + coronary artery bypass grafting + thrombolytic therapy. Model 5: chest pain + pain left
arm + dyspnea + sweating + vomiting + nausea + jaw pain. Model 6: right bundle branch block + left bundle branch block + atrial fibrillation + -
ventricular tachycardia. Model 7: ST-segment elevation myocardial infarction + non-ST-segment elevation myocardial infarction + myocardial
infarction status.
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than in those without diabetes. Based on a study on diabetes
patients with multi-vessel coronary disease, CABG was more
effective in reducing mortality and led to fewer repeated
revascularizations than PCI [23]. The result of this study is not
consistent with our study finding of the ratio of mortality
following CABG being higher than mortality following PCI. The
reason may be technique used, the frequency of use and level
of professionals’ skill, and the different characteristics and
risk factors in the studied patients. Lee et al. assessed the
efficacy and safety of CABG compared to drug-eluting stenting
(DES) in patients with diabetes mellitus and multivessel
coronary artery disease (CAD) and found that, PCI with DES
was safe and could represent a viable alternative to CABG for
selected patients with diabetes and multivessel CAD [24]. Our
study showed that in diabetes patients, mortality following
CABG was higher than that following thrombolytic therapy. In
our study on a group of Iranian patients, use of PCI in diabetes
patients was associated with lower mortality compared to
CABG and treatment with thrombolytic therapy. In the study
of Juutilainen et al., the HR of mortality from cardiovascular
diseases was 1.9 (1.4–2.6). Juutilainen et al. used the patients’
self-report to classify diabetes and MI [22] and hence bias is
probable, which could explain the inconsistency between the
present investigation and Juutilainen et al. findings. To answer
the question whether the risk of cardiovascular disease is the
same in diabetes patients without MI history and non-diabetes
patients with MI history, Bulugahapitiya et al. established that
diabetes patients without MI history were at lower (by 43%)
risk of all cardiovascular diseases compared to non-diabetes
patients with MI history. In this study, HR was detected 0.56
[4]. Moreover, Haffner et al. showed that, non-diabetes
patients with MI history and diabetes patients without MI
history were at equal risk of coronary heart disease (CHD)
incidence, which is not consistent with our study. A meta-
analysis reviewed 13 seminal studies and reported no supportfor the hypothesis that diabetes is a coronary heart disease
equivalent. However, diabetes was reported as an important
risk factor for cardiovascular diseases [4]. Kanaya et al.
reported gender-based disparity in mortality from CHD
concurrent with type 2 diabetes, and found that, OR of
mortality from CHD was higher in women with diabetes than
in men with diabetes. OR of death for diabetes was 2.3 and 2.9
in men and women, respectively, and HR of death for gender
was not significant when other variables were adjusted [25]. In
our study, although the adjusted OR of mortality for diabetes
was higher in women than in men, the difference was not
significant, which is consistent with the result of the study of
Kanaya et al. [25]. In the present study, OR of mortality was
significantly higher in women than in men and the mortality
from MI was significantly higher in diabetes patients than in
non diabetes patients, consistent with the studies of Cho et al.
and Zuanetti et al. which investigated the diabetes contribu-
tion in post-MI patients receiving fibrinolytic therapy [26,27].
Although use of PCI, CABG, and thrombolytic therapy in our
study was higher in those with or without diabetes, mortality
was higher in those with diabetes when these therapies were
controlled for in analysis. The higher mortality in diabetes
patients in the present study could be explained through
comorbidities such as hypertension, age, gender, cholester-
olemia, RBBB, and LBBB. In the meta-analysis conducted by
Lee et al., the relative risk of death from CHD for diabetes was
higher in women (2.58) than in men (1.85) [24]. Our study
confirms the findings of Lee et al. Lee et al. reported that
mortality from MI was higher in women with diabetes than in
men without diabetes. They also showed that, the risk of death
was insignificantly higher in women with diabetes than in
men with diabetes, which was not consistent with our
findings. Cho et al. found that 2.5% of men had diabetes
and they smoked more frequently than those without [27].
Similarly, the study of Pyorala et al. found that, use of
Simvastatin in diabetes patients, as compared to non diabetes
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[28]. In contrast, use of PCI, CABG, and thrombolytic therapy in
our study did not decrease the risk of death in patients with
diabetes compared to those without. In our study, use of PCI
could be considered a protective factor against death for non
diabetes patients, but it was not significant for diabetes
patients. Our findings are consistent with a study reporting
that diabetes and variables such as age, gender, and
hypertension were the main determinants of acute coronary
heart syndromes [29]. In the studies conducted by Hu et al.,
Merry et al., and Zaliunas et al., age, Killip class, hypertension,
and STEMI were predictors of hospital mortality from coronary
heart syndrome, which is in agreement with the present study
[30–32]. However, our findings are not consistent with Zaliunas
et al. study, which showed that interventional therapies were
a cause of decreased mortality in diabetes patients [30]. This
inconsistency was explored in our study by enrolling a large
sample size including patients with or without diabetes and
investigating the association between treatment strategy and
hospital mortality, using MI and definite diabetes diagnosis,
and avoiding use of self-reporting. Failure to include diabetes
duration in the model was one of the limitations of the present
study, which should be considered in future studies.
5. Conclusions
The hospital mortality from MI following use of PCI,
thrombolytic therapy, and CABG was, respectively, 7.28%,
13.23%, and 15.74% in diabetes patients and 4.72%, 15.57%, and
11.4% in non diabetes patients. OR and HR of death from MI
following these treatments was significantly higher in diabe-
tes patients than in patients without diabetes. The mortality
from MI in patients with and without diabetes was higher in
Iran than reported from some other countries. Also, use of the
above therapies appeared considerably lower in Iran than in
other countries. The mortality from MI in diabetes patients
following PCI was lower than the mortality following CABG.
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